Core Insights - The PatentVest Pulse report highlights a significant gap between rising valuations of humanoid robotics startups and their lack of intellectual property protections, indicating potential long-term value risks [1][2] - The report serves as a strategic guide for investors, board members, and CEOs to identify which companies are well-positioned and which are vulnerable in the humanoid robotics sector [1][2] Industry Analysis - The analysis benchmarks the IP portfolios of leading startups such as Figure AI, Sanctuary AI, Apptronik, Tesla Optimus, Neura Robotics, Engineered Arts, 1X Technologies, and Collaborative Robotics, mapping over 11,000 patent families across 794 entities globally [3] - The report emphasizes the importance of IP as a critical factor for scaling, licensing, and capturing long-term value in the humanoid robotics industry [2] Emerging Leaders - Figure AI is gaining attention and capital, while Sanctuary AI is building a defensible platform, with other companies like Neura Robotics, Apptronik, and Agility Robotics also making strides through focused IP strategies [6] - Sanctuary AI is noted as one of the few startups among the top 20 global patent holders, highlighting the rarity of defensible positions in the industry [6] Corporate Landscape - Major industrial players such as Sony, UBTECH, Honda, Toyota, Hyundai, Alphabet, and Samsung hold over 11,000 humanoid robotics patent families, indicating significant corporate consolidation in the IP landscape [6] - University-led innovation is crucial, with institutions like Tsinghua University, AIST, and the University of Tokyo holding key patents that influence core technologies and future commercialization opportunities [6]

Core Viewpoint - CAVA Healthcare Inc has appointed Barbara Sharp as the new Chief Executive Officer (CEO), effective immediately, marking a significant leadership change for the company [1]. Leadership Experience - Barbara Sharp brings over three decades of leadership experience across public, private, and nonprofit sectors, including roles such as Mayor of North Vancouver and Divisional Director of Employee Relations for The Salvation Army [2]. - She has served as a Special Advisor for Conflict Resolution at the University of the Fraser Valley and is the founder of Barbara Sharp Solutions, a consulting firm focused on strategic planning and organizational development [3]. Academic Credentials - Sharp holds a Master of Arts in Conflict Analysis and Management and has ongoing coursework in Trauma-Informed Practices, along with multiple professional certifications in labour relations and mediation [4]. Strategic Focus - Under Sharp's leadership, CAVA Healthcare aims to focus on innovation, collaboration, and making a positive impact on healthcare, with an emphasis on equity and sustainable development [4]. Company Overview - CAVA Healthcare is a specialty biotechnology company dedicated to advancing drug development for unmet medical needs, particularly in neurodegeneration and inflammation, with a focus on Alzheimer's Disease and oncology-related treatments [5].

Core Insights - Orchestra BioMed is expanding its intellectual property portfolio, securing 10 new patents related to hypertension treatment, bringing the total to 120 patents in this area [2][6] - The company has also increased its patent estate for heart failure treatment to 17 issued patents, enhancing its overall IP platform [2][6] - AVIM therapy is currently being evaluated in the BACKBEAT global pivotal study for treating uncontrolled hypertension in patients indicated for pacemakers, highlighting its potential impact on broader cardiovascular health [2][8] Intellectual Property Expansion - The global intellectual property portfolio for AVIM therapy includes patent protection in key markets such as the United States, Europe, Japan, and China [3] - The hypertension-specific patent estate now consists of 46 issued U.S. patents and 91 patents outside the U.S., collectively comprising over 2100 claims related to hypertension and heart failure [6] Strategic Collaborations - Orchestra BioMed has a strategic collaboration with Medtronic for the development and commercialization of AVIM therapy, focusing on hypertension treatment in pacemaker-indicated patients [4] - The company is also partnered with Terumo for the development of the Virtue Sirolimus AngioInfusion™ Balloon for treating atherosclerotic artery disease [4] Regulatory Designations - AVIM therapy has received Breakthrough Device Designation from the U.S. FDA for treating uncontrolled hypertension with increased cardiovascular risk, which may expedite its development and market access [2][6][9]

Core Insights - ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application related to an intragastric balloon system, which includes a swallowable capsule and a degradable release valve designed for natural excretion after deflation [1][2] - The patent, once issued, will provide protection until at least January 2031, potentially extending further with a Patent Term Extension [1] - The company has secured over 50 patents related to its intragastric balloon system since its initial application in 2011, resulting in a total of more than 160 patents issued and pending [2] Company Overview - ReShape Lifesciences is a leading company in the weight loss and metabolic health solutions sector, offering a range of products and services aimed at managing obesity and metabolic diseases [3] - The company’s FDA-approved products include the Lap-Band and Lap-Band 2.0 Flex Systems, which provide minimally invasive treatments for obesity, and the Obalon balloon technology, a non-surgical, swallowable intra-gastric balloon [3] Recent Developments - ReShape Lifesciences has entered into an asset purchase agreement with Biorad Medisys, under which it will sell substantially all of its assets, including the Lap-Band System and Obalon Gastric Balloon System, to Biorad [4]

Core Insights - The core viewpoint of the article highlights ZTE Corporation's significant investment in research and development (R&D) over the past 20 years, showcasing its commitment to innovation and intellectual property management [2][3] Group 1: R&D Investment and Strategy - ZTE has increased its R&D investment by over 10 times in the past 20 years, with R&D expenses projected to account for approximately 20% of revenue in 2024 [2] - By the end of 2024, ZTE will have applied for a total of 93,000 global patents, with 48.5% of its employees dedicated to R&D [2] - The company has established 11 R&D bases across the country, with over 40% of its employees holding a master's degree or higher [2] Group 2: Intellectual Property Achievements - ZTE has achieved patent coverage in 55 countries and regions globally, with 48,000 authorized patents and over 90% being invention patents [3] - The company has applied for approximately 5,500 chip-related patents and over 5,000 AI patents, with nearly 50% of the AI patents already authorized [3] - ZTE ranks among the top five global patent holders in terms of effective global patent families, having disclosed nearly 7,000 families of essential 5G standard patents [3] Group 3: Recognition and Awards - ZTE has received numerous accolades for its patent achievements, including 11 gold awards, 3 silver awards, and 39 excellence awards in the China Patent Awards, as well as 30 National Science and Technology Progress Awards [3] - The recognition reflects ZTE's systematic advantages in technology R&D, patent layout, and industrial application [3]

Group 1 - Innventure, Inc. will host two events during the IP Leadership Executive Summit on April 15 and 16, and will also speak at the LES-SVC's 21st Annual Chapter Conference on April 17 [1][2] - The IP Leadership Executive Summit is a two-day forum focusing on the future of intellectual property and technology solutions, with Innventure as a platinum partner [2] - Innventure will conduct a workshop titled "Breaking Industry Boundaries: The Reimagined IP Commercialization Playbook" on April 15, allowing participants to explore unlocking value from technology innovations [3] Group 2 - A roundtable discussion titled "Maximizing Value: Where the Rubber (TIRE) Meets the Road" will also be held on April 15, moderated by Innventure's Vice-President of Strategic Partnerships, Brice Dubosq [4] - The LES Silicon Valley Chapter Conference will address trends and challenges in innovation and IP deal-making, with the theme "The Silicon Valley Deal Machine" [4] - Innventure is a gold sponsor of the event, with Executive Chairman Mike Otworth delivering a keynote speech on April 17 titled "Breaking Free: Unleashing Innovation Beyond Corporate Wall" [5] Group 3 - Innventure's Vice President of Business Development/Strategic Partnerships, Gayle Anderson, will participate in a panel discussion on "Scaling Success: Business Models to Scale-up and Scale-out" on April 17 [5] - The panel will focus on business models that support innovation and commercialization deal-making, particularly in the context of AI-driven hardware breakthroughs [6] - Innventure specializes in founding, funding, and operating companies focused on transformative technology solutions, aiming for a target enterprise value of at least $1 billion [6]

As filed with the U.S. Securities and Exchange Commission on September 29, 2023 Registration No. 333-274331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 WiSA Technologies, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3674 30-1135279 (I.R.S. Employer Identif ...